Prostate cancer relapse predicted with blood test

A simple blood test could be used by doctors to predict the chances that a prostate cancer sufferer will relapse after treatment.

Scientists have uncovered genetic abnormalities that were associated with recurrence rates. They also discovered that the so-called copy number variations (CNV) would dictate whether a cancer was likely to be aggressive or slow-growing.

Chief investigator Dr Jian-Hua Luo, from the University of Pittsburgh School of Medicine in the US, said the finding could inform treatment decisions.

"For a patient diagnosed with prostate cancer, CNV analysis done on blood or normal tissues would eliminate the need for additional invasive procedures to decide a treatment mode," Dr Luo said.

In fact, blood testing for the abnormalities successfully predicted relapses in 81 per cent of cases - including 69 per cent of fast-growing cases.

Recently scientists at the University of Chicago Medicine demonstrated that a compound found in beehives - caffeic acid phenethyl ester - can slow the growth of prostate cancer tumours.



Latest news

Suffering in silence could be killing you!

Spire Parkway Hospital has invested in a haemorrhoid-treatment system that allows the patient to...

Horder Healthcare are delighted to announce that their new and improved website has now launched.

Prostate cancer relapse predicted with blood test
Connect with us on: